Renvistobart

A4DAB224 | Phase-II

Target TIGIT/WUCAM/VSTM3

Isotype / Subclass G1 / None

Company

Bristol-Myers Squibb Compugen Multiple Myeloma Research Consortium Ono Pharmaceutical

Clinical Status Phase-II

Format Whole mAb

Synonyms

BMS-986207 BMS 986207 BMS986207

pH Formulation —

IMGT PubChem (404720502) PubChem (472411723) PubChem (485483333) PubChem (485511901) Thera-SAbDab YAbS

Avg A4D Score

-0.6157

Score Range

-0.62 to -0.61

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB224_8szy_H_L	8szy	100%	-0.6217	6.5	4.0	-0.0264	-0.7144
A4DAB224_8szy_I_M	8szy	100%	-0.6096	6.5	4.0	-0.0515	-0.6967